115 results match your criteria: "Grey Nuns Community Hospital[Affiliation]"

Background: Despite comparatively low rates of COVID-19 admissions and recorded deaths in sub-Saharan Africa (SSA), the pandemic still had significant impact on health service utilization (HSU). The aim of this scoping review is to synthesize the available evidence of HSU in SSA during the pandemic, focusing on types of studies, changes in HSU compared with the pre-pandemic period, and changes among specific patient groups.

Methods: The scoping review was guided by the methodological framework for conducting scoping reviews developed by Arksey and O'Malley.

View Article and Find Full Text PDF
Article Synopsis
  • The BETTER WISE study aimed to evaluate a cancer and chronic disease prevention program's effectiveness by comparing outcomes between participants facing financial difficulties versus those who did not.
  • The study analyzed data from a cluster-randomized trial involving 596 participants from 59 physicians across 13 clinics, comparing a 1-hour intervention visit to usual care.
  • Results indicated that participants without financial difficulties in the intervention group had a higher completion rate of eligible preventive actions (29%) compared to the control group (23%), while there was no significant difference in those with financial difficulties.
View Article and Find Full Text PDF

Background & Aims: Upadacitinib, an oral Janus kinase inhibitor, achieved significantly higher rates of clinical remission and endoscopic response vs placebo during induction (U-EXCEL [NCT03345849], U-EXCEED [NCT03345836]) and maintenance (U-ENDURE [NCT03345823]) treatment in patients with moderate-to-severe Crohn's disease. Prior biologic failure is often associated with reduced responses to subsequent therapies. This post hoc analysis assessed upadacitinib efficacy by prior biologic failure status.

View Article and Find Full Text PDF

Quality of Life After Intravenous Thrombolysis for Acute Ischemic Stroke: Results From the AcT Randomized Controlled Trial.

Stroke

March 2024

Department of Community Health Sciences, University of Calgary, AB, Canada (T.T.S., O.I.A., A.A., M.A.A., S.B.C., A.M.D., M.D.H., B.L., B.K.M.).

Background: Recent evidence from thrombolysis trials indicates the noninferiority of intravenous tenecteplase to intravenous alteplase with respect to good functional outcomes in patients with acute stroke. We examined whether the health-related quality of life (HRQOL) of patients with acute stroke differs by the type of thrombolysis treatment received. In addition, we examined the association between the modified Rankin Scale score 0 to 1 and HRQOL and patient-reported return to prebaseline stroke functioning at 90 days.

View Article and Find Full Text PDF

Background: Though intravenous (IV) ketamine and intranasal (IN) esketamine are noted to be efficacious for treatment-resistant depression (TRD), access to each of these treatments within healthcare systems is limited due to cost, availability, and/or monitoring requirements. IV ketamine has been offered at two public hospital sites in Edmonton, Canada since 2015. Since then, demand for maintenance ketamine treatments has grown.

View Article and Find Full Text PDF

Background: Understanding sex differences in stroke care is important in reducing potential disparities. Our objective was to explore sex differences in workflow efficiency, treatment efficacy, and safety in the AcT trial (Alteplase Compared to Tenecteplase).

Methods: AcT was a multicenter, registry-linked randomized noninferiority trial comparing tenecteplase (0.

View Article and Find Full Text PDF

Background: The AcT (Alteplase Compared to Tenecteplase) randomized controlled trial showed that tenecteplase is noninferior to alteplase in treating patients with acute ischemic stroke within 4.5 hours of symptom onset. The effect of time to treatment on clinical outcomes with alteplase is well known; however, the nature of this relationship is yet to be described with tenecteplase.

View Article and Find Full Text PDF

Background: Cancer and chronic diseases are a major cost to the healthcare system and multidisciplinary models with access to prevention and screening resources have demonstrated improvements in chronic disease management and prevention. Research demonstrated that a trained Prevention Practitioner (PP) in multidisciplinary team settings can improve achievement of patient level prevention and screening actions seven months after the intervention.

Methods: We tested the effectiveness of the PP intervention in a pragmatic two-arm cluster randomized controlled trial.

View Article and Find Full Text PDF

Background: Carotid tandem lesions ((TL) ⩾70% stenosis or occlusion) account for 15-20% of acute stroke with large vessel occlusion.

Aims: We investigated the safety and efficacy of intravenous tenecteplase (0.25 mg/kg) versus intravenous alteplase (0.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates whether tenecteplase, an alternative to alteplase, is equally safe and effective for treating patients with acute ischemic stroke caused by large vessel occlusion (LVO).
  • Conducted as part of the ACT trial in Canada, this analysis involved 1,600 patients with disabling strokes enrolled from 22 stroke centers over a span of two years, where they were randomly assigned to receive either medication.
  • The primary outcome measured was the likelihood of achieving a modified Rankin scale score of 0-1 at 90 days, with secondary outcomes including mortality rates, rates of symptomatic intracerebral hemorrhage, and successful reperfusion rates.
View Article and Find Full Text PDF

Rationale: Renal tubular acidosis (RTA) is a cause of non-anion gap metabolic acidosis (NAGMA) that is infrequently diagnosed and is due to various underlying etiologies that impair the kidney's ability to retain bicarbonate or excrete acid. Ibuprofen is an over-the-counter non-steroidal anti-inflammatory medication that is used by patients widely for a variety of reasons. Although it is well known that ibuprofen and other non-steroidal anti-inflammatory drugs may have nephrotoxic effects, the role of ibuprofen as a cause of RTA and hypokalemia is not well recognized.

View Article and Find Full Text PDF

Purpose: The BETTER WISE (Building on Existing Tools to Improve Chronic Disease Prevention and Screening in Primary Care for Wellness of Cancer Survivors and Patients) intervention is an evidence-based approach to prevention and screening for cancers and chronic diseases in primary care that also includes comprehensive follow-up for breast, prostate and colorectal cancer survivors. We describe the process of harmonizing cancer survivorship guidelines to create a BETTER WISE cancer surveillance algorithm and describe both the quantitative and qualitative findings for BETTER WISE participants who were breast, prostate or colorectal cancer survivors. We describe the results in the context of the COVID-19 pandemic.

View Article and Find Full Text PDF

The aim of the BETTER WISE intervention is to address cancer and chronic disease prevention and screening (CCDPS) and lifestyle risks in patients aged 40-65. The purpose of this qualitative study is to better understand facilitators and barriers to the implementation of the intervention. Patients were invited for a 1-h visit with a prevention practitioner (PP), a member of a primary care team, with specific skills in prevention, screening, and cancer survivorship.

View Article and Find Full Text PDF

Background: Accumulating evidence from clinical trials suggests that a lower (restrictive) hemoglobin threshold (<8 g/dL) for red blood cell (RBC) transfusion, compared with a higher (liberal) threshold (≥10 g/dL) is safe. However, in anemic patients with acute myocardial infarction (MI), maintaining a higher hemoglobin level may increase oxygen delivery to vulnerable myocardium resulting in improved clinical outcomes. Conversely, RBC transfusion may result in increased blood viscosity, vascular inflammation, and reduction in available nitric oxide resulting in worse clinical outcomes.

View Article and Find Full Text PDF

Association between Goals of Care Designation orders and health care resource use among seriously ill older adults in acute care: a multicentre prospective cohort study.

CMAJ Open

November 2022

Division of Palliative Medicine, Department of Oncology (Earp), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Covenant Health Palliative Institute (Fassbender), Grey Nuns Community Hospital, St. Marguerite Health Services Centre; Division of Palliative Care Medicine, Department of Oncology (Fassbender), University of Alberta, Edmonton, Alta.; Department of Community Health Sciences (King), Cumming School of Medicine, University of Calgary; Division of Palliative Medicine, Department of Oncology (Douglas), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Covenant Health Palliative Institute (Douglas), Grey Nuns Community Hospital, St. Marguerite Health Services Centre, Edmonton, Alta.; Division of Palliative Medicine, Department of Oncology (Biondo), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Department of Medicine and Oncology (Palliative Care) (Brisebois) and Department of Medicine (Davison, Sia), University of Alberta, Edmonton, Alta.; Division of Palliative Medicine, Department of Oncology (Wasylenko), Cumming School of Medicine, University of Calgary, Calgary, Alta.; John Dossetor Health Ethics Centre, Faculty of Medicine and Dentistry (Wasylenko), University of Alberta, Edmonton, Alta.; Alberta Health Services, South Zone Seniors Health Integrated Home Care/Palliative Care (Esau), Edmonton, Alta.; Departments of Oncology, Medicine and Community Health Sciences (Simon), University of Calgary, Calgary, Alta.

Background: The Goals of Care Designation (GCD) is a medical order used to communicate the focus of a patient's care in Alberta, Canada. In this study, we aimed to determine the association between GCD type (resuscitative, medical or comfort) and resource use during hospitalization.

Methods: This was a prospective cohort study of newly hospitalized inpatients in Alberta conducted from January to September 2017.

View Article and Find Full Text PDF

Ketamine is a versatile medication with an emerging role for the treatment of numerous psychiatric conditions, including treatment resistant depression. Current psychiatry guidelines for its intravenous administration to treat depression recommend regular blood pressure monitoring and an aggressive approach to potential transient hypertensive episodes induced by ketamine infusions. While this approach is aimed at ensuring patient safety, it should be updated to align with best practice guidelines in the management of hypertension.

View Article and Find Full Text PDF

Depression has been associated with adverse outcomes in patients with cardiac disease. Data on its prevalence and the factors influencing it are limited in the cardiac rehabilitation program (CRP) setting. To elucidate the prevalence of and the factors that influence depression in patients attending CRP.

View Article and Find Full Text PDF
Article Synopsis
  • A phase 3 clinical trial assessed the safety and effectiveness of rivipansel, an E-selectin antagonist, in 345 patients (adults and children) with vaso-occlusive crises (VOC) requiring hospitalization.
  • The study found that rivipansel did not significantly improve the primary endpoint of time to readiness for discharge compared to placebo, although it did notably reduce soluble E-selectin levels in the treatment group.
  • A post hoc analysis suggested that administering rivipansel early after VOC pain onset could significantly decrease the time to discharge and reduce opioid use, indicating that the timing of treatment may be key for better outcomes.
View Article and Find Full Text PDF

Background: Intravenous thrombolysis with alteplase bolus followed by infusion is a global standard of care for patients with acute ischaemic stroke. We aimed to determine whether tenecteplase given as a single bolus might increase reperfusion compared with this standard of care.

Methods: In this multicentre, open-label, parallel-group, registry-linked, randomised, controlled trial (AcT), patients were enrolled from 22 primary and comprehensive stroke centres across Canada.

View Article and Find Full Text PDF

Palliative care stakeholders in Canada.

Health Res Policy Syst

June 2022

Covenant Health Palliative Institute, c/o Grey Nuns Community Hospital, Room 416 St. Marguerite Health Services Centre, 1090 Youville Drive West, Edmonton, AB, T6L 0A3, Canada.

Background: Improving access to palliative care for Canadians requires a focused collective effort towards palliative and end-of-life care advocacy and policy. However, evolution of modern palliative care in Canada has resulted in stakeholders working in isolation. Identification of stakeholders is an important step to ensure that efforts to improve palliative care are coordinated.

View Article and Find Full Text PDF

Intravenous (IV) ketamine is increasingly used off-label at subanesthetic doses for its rapid antidepressant effect, and intranasal (IN) esketamine has been recently approved in several countries for treating depression. The clinical utility of these treatments is limited by a paucity of publicly funded IV ketamine and IN esketamine programs and cost barriers to private treatment programs, as well as the drug cost for IN esketamine itself, which makes generic ketamine alternatives an attractive option. Though evidence is limited, use of non-parenteral racemic ketamine formulations (oral, sublingual, and IN) may offer more realistic access in less rigidly supervised settings, both for acute and maintenance treatment in select cases.

View Article and Find Full Text PDF

Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial.

CMAJ

February 2022

Niagara Health (Ali, Tsang), St. Catharines, Ont.; Biomedical Sciences (Azher), Memorial University of Newfoundland, St. John's, Nfld.; William Osler Health System (Baqi, Binnie, Borgia, Havey), Brampton, Ont.; Hôpital du Sacré-Coeur de Montréal (Cavayas), Montréal, Que.; Emergency Department (Chagnon), Montfort Hospital, Ottawa, Ont.; Departments of Pediatrics (Fontela, Papenburg), Surgery and Critical Care Medicine (Khwaja), McGill University, Montréal, Que.; Divisions of Infectious Diseases (Cheng, Costiniuk, Harrison, M. Klein, Kronfli, T. Lee, Semret, Yansouni), Chronic Viral Illness Service (Costiniuk, M. Klein), Medical Microbiology (Cheng, Yansouni), Internal Medicine (Malhamé, T. Lee), and Infectious Diseases and Immunity in Global Health Program (M. Klein, Kronfli, T. Lee, Papenburg) McGill University Health Centre, Montréal, Que.; Division of Respirology (Lim, Weatherald), Cumming School of Medicine (Conly, Somayaji), and Departments of Critical Care Medicine (Parhar), Repiratory Medicine (Tremblay) and Interventional Pulmonary Medicine (Vakil), University of Calgary, Calgary, Alta.; Health Sciences Centre (Tremblay), University of Calgary, Calgary, Alta.; Discipline of Laboratory Medicine (Daley), Memorial University of Newfoundland, St. John's, Nfld.; Lion's Gate Hospital (Douglas), Vancouver, BC; CCTS at Sunnybrook Research Institute - Centre for Clinical Trial Support (Downey, G. Klein, Lau, Longo, Mangoff, Mergler, Patel, Rajakumaran, Roba-Oshin, Saleem, Tobin, Todd), Toronto, Ont.; Departments of Medicine and Critical Care Medicine (Fowler) and Division of Infectious Diseases (Daneman), Sunnybrook Hospital, Toronto, Ont.; Department of Critical Care Medicine (Pinto, Rishu), Sunnybrook Health Sciences Centre, Toronto, Ont.; Division of Critical Care (Duan), Department of Medicine (Tsang), McMaster University, Hamilton, Ont.; Departments of Anesthesiology (Carrier), Medicine (Duceppe, Kolan), Intensive Care Medicine (Carrier) and Internal Medicine (Duceppe, Kolan) and Internal Medicine Service (Durand), Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Que.; Departments of Medicine (English) and Infectious Diseases (McGuinty), The Ottawa Hospital, Ottawa, Ont.; Department of Medicine (English), Ottawa Hospital Research Institute, Ottawa, Ont.; Niagara Health (Farjou, Tsang), St. Catharines, Ont.; Markham Stouffville Hospital (Fera), Markham, Ont.; Division of General Internal Medicine (Fralick), Department of Medicine, Sinai Health System; Department of Medicine and Critical Care Medicine (Geagea, Lostun), North York General Hospital, Toronto, Ont.; Departments of Pediatrics (Murthy) and Pathology and Laboratory Medicine (Grant), Faculty of Medicine, University of British Columbia, Vancouver, BC; Island Health Authority (Ovakim), University of British Columbia, Vancouver, BC; Division of Infectious Diseases (Hoang), Department of Medicine, Grey Nuns Community Hospital, Edmonton, Alta.; Department of Pharmacology and Therapeutics (Kelly), George and Fay Yee Centre for Healthcare Innovation, University of Manitoba; Departments of Infectious Disease and Medical Microbiology (Keynan) and Internal Medicine (Zarychanski), University of Manitoba, Winnipeg, Man.; Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (Lamontagne), Sherbrooke, Que.; Departments of Critical Care (MacIntyre, Sligl) and Medicine (Singh, Smith), Division of Infectious Diseases (O'Neil), University of Alberta, Edmonton, Alta.; Department of Critical Care Medicine (Munan), Misericordia Community Hospital, Edmonton, Alta.; Misericordia Hospital - Covenant Health (Scherr), Edmonton, Alta.; St. Joseph's Health Care (Parvathy), London, Ont.; Department of Medicine (Perez-Patrigeon), Queen's University, Kingston, Ont.; Queensway Carleton Hospital (Rushton), Nepean, Ont.; Public Health Agency of Canada (Salvadori), Ottawa, Ont.; Unity Health Toronto (Schwartz), Toronto, Ont.; Dalla Lana School of Public Health (N. Lee, Schwartz), University of Toronto, Toronto, Ont.; Department of Medicine (Silverman), Western University, London, Ont.; Division of Infectious Diseases (Tan), St. Michael's Hospital, Toronto, Ont.; Department of Anesthesiology and Critical Care Medicine (Turgeon, Tran), CHU de Québec-Université Laval, Québec, Que.

Background: The role of remdesivir in the treatment of patients in hospital with COVID-19 remains ill defined in a global context. The World Health Organization Solidarity randomized controlled trial (RCT) evaluated remdesivir in patients across many countries, with Canada enrolling patients using an expanded data collection format in the Canadian Treatments for COVID-19 (CATCO) trial. We report on the Canadian findings, with additional demographics, characteristics and clinical outcomes, to explore the potential for differential effects across different health care systems.

View Article and Find Full Text PDF

Adipose-derived mesenchymal stem cell exosomes inhibit transforming growth factor-β1-induced collagen synthesis in oral mucosal fibroblasts.

Exp Ther Med

December 2021

Hunan Key Laboratory of Oral Health Research, Hunan Xiangya Stomatological Hospital, Central South University, Changsha, Hunan 410000, P.R. China.

Oral submucosal fibrosis (OSF) is a potentially malignant oral disorder that requires the further development of advanced treatment strategies. TGF-β1 has been reported to be the main trigger for the increased collagen production and reduced activity of matrix degradation pathways in OSF. Exosomes are key mediators of paracrine signaling that have been proposed for direct use as therapeutic agents for tissue repair and regeneration.

View Article and Find Full Text PDF

Background: South Asians have a greater predisposition to cardiac events, compared to Caucasians. Although cardiac rehabilitation programs (CRPs) are known to improve outcomes, data are sparse regarding benefits acquired by South Asians vs Caucasians. The objective of the current study was to determine the outcomes of South Asian patients undergoing CRPs, compared to Caucasian patients.

View Article and Find Full Text PDF

Background: Anxiety symptoms are common in patients with major depressive disorder (MDD) and usually confer worse treatment outcomes. The long-term, open-label AtWoRC study in working patients with MDD treated with vortioxetine demonstrated a significant correlation between severity of anxiety symptoms and impaired work productivity. This analysis was undertaken to further explore clinical characteristics and treatment outcomes in patients with different levels of severity of anxiety symptoms at baseline.

View Article and Find Full Text PDF